Recombinant CC10 Peptide Blocks Viral Attachment to Prevent Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively treating and preventing viral respiratory infections, including influenza, ebola, and coronavirus, due to rapid mutation leading to drug-resistant strains and lack of approved anti-viral medications.
Innovation Solution
Administration of recombinant human CC10 (rhCC10) via intranasal, intravenous, or inhaled routes to reduce pulmonary viral titers and inhibit viral replication, potentially combined with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral agents are used to treat influenza, then viral replication is inhibited, but drug-resistant strains develop due to rapid mutation
Solution Approach 1:
The patent employs a small peptide (15-30 amino acids) as an intermediary that binds to the N-terminal region of influenza virus hemagglutinin, blocking viral attachment to host cells without directly inhibiting viral replication enzymes. This mediator approach prevents resistance development because the peptide targets a conserved structural region rather than a mutable functional enzyme.
Solution Approach 2:
The treatment prevents viral attachment to host cells before infection can occur. By blocking the initial attachment step through peptide-hemagglutinin binding, the virus is prevented from entering cells and initiating replication, thereby stopping the infection process at its earliest stage.
2Ease of manufacture
If antiviral medications are developed for new viral infections, then treatment options are provided, but the rapid mutation rate of viruses leads to drug resistance
Solution Approach 1:
The patent utilizes the conserved structural parameters of the hemagglutinin N-terminal region across different influenza strains. By targeting this invariant structural parameter rather than variable regions, the peptide maintains effectiveness against multiple strains including drug-resistant variants, providing reliable long-term treatment efficacy.
3Productivity
If existing antiviral therapies are used, then some viral replication is inhibited, but they are inadequate for effectively treating and preventing viral respiratory infections
Solution Approach 1:
The patent extracts and utilizes only the essential 15-30 amino acid N-terminal region of hemagglutinin that is responsible for viral attachment. This extracted peptide fragment is sufficient to block viral binding without requiring the entire viral protein, creating a simplified yet highly effective treatment that overcomes the limitations of existing therapies.
Data Source
AI summary
Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin and secretoglobin 1A1 (SCGB1A1), to reduce virus titers in the tissues of patients, particularly influenza, ebola, and coronavirus titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza, ebola, and coronavirus infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza, ebola, and coronavirus infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans.